NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









uMed

uMed

Private
LondonHealthcare & Life Scienceshttps://umed.io/

Last Round

Series A

Jul 5, 2023

Total Funding Raised

$18.7M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

uMed is a health and research technology company that provides a platform to automate clinical study processes and connect healthcare providers with research programs.

Sector

Healthcare & Life Sciences

Verticals

Clinical Trials, Patient Engagement, Healthcare Analytics

Business Model

B2B2C

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Application

Keywords

clinical trial recruitmentreal-world evidenceRWEpatient recruitmentelectronic health recordEHRpatient matchingclinical research softwaredata as a serviceDaaSclinical trial softwarepatient engagementlongitudinal health dataclinical trial techhealthtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

uMed Comparables

Compare uMed with similar companies based on industry and business-model similarity.

uMed comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Verana Health
79%
Paradigm Health
76%
TriNetX
76%

uMed Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 5, 2023
SeedDec 1, 2020
Pre SeedOct 8, 2019

Key People

Founding team and executive leadership

Matt Wilson

CEO Founder

Founding Team

uMed Investors

Notable investors and investment history

uMed investors
InvestorRounds
Playfair CapitalSeed, Series A, Pre Seed
Albion CapitalSeries A, Seed
Delin VenturesSeed, Series A
11.2 CapitalSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 1, 2025

    Access-PD Parkinson's Disease research cohort is active.

  • Oct 1, 2025

    Network now includes over 6.5 million patients across UK and US.

uMed Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

uMed Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about uMed's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range94
Year Founded2017
Last FundingJul 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.